MoonLake Immunotherapeutics (MLTX) Assets (2020 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Assets of $400.4 million for Q1 2026, down 21.69% year-over-year from $511.3 million in Q1 2025, and down 5.67% quarter-over-quarter from $424.4 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Assets (2020 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Assets history runs 7 years deep, the most recent figure standing at $400.4 million for Q1 2026.
- In Q1 2026, Assets fell 21.69% year-over-year to $400.4 million; the TTM figure through Mar 2026 stood at $400.4 million (down 21.69% YoY), while the FY2025 annual figure was $424.4 million, down 11.19% from the prior year.
- Assets for Q1 2026 stood at $400.4 million, down from $424.4 million in the prior quarter.
- The five-year high for Assets was $564.1 million in Q1 2024, with the low at $66.8 million in Q1 2023.
- The 5-year median for Assets is $460.1 million (2025), against an average of $377.1 million.
- The sharpest annual moves came in 2023 and 2024: Assets slumped 71.11% in 2023, then jumped 744.53% in 2024.
- MoonLake Immunotherapeutics' Assets stood at $76.8 million in 2022, then soared by 585.21% to $526.5 million in 2023, then decreased by 9.23% to $477.9 million in 2024, then fell by 11.19% to $424.4 million in 2025, then fell by 5.67% to $400.4 million in 2026.
- Business Quant data shows MLTX's Assets at $400.4 million in Q1 2026, $424.4 million in Q4 2025, and $414.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 573.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 573.95 Mn |
| Mar 31, 2026 | 400.37 Mn |
| Dec 31, 2025 | 424.43 Mn |
| Sep 30, 2025 | 414.34 Mn |
| Jun 30, 2025 | 460.10 Mn |
| Mar 31, 2025 | 511.26 Mn |
| Dec 31, 2024 | 477.93 Mn |
| Sep 30, 2024 | 518.21 Mn |
| Jun 30, 2024 | 544.88 Mn |
| Mar 31, 2024 | 564.12 Mn |
| Dec 31, 2023 | 526.54 Mn |
| Sep 30, 2023 | 500.22 Mn |
| Jun 30, 2023 | 506.62 Mn |
| Mar 31, 2023 | 66.80 Mn |
| Dec 31, 2022 | 76.84 Mn |
| Sep 30, 2022 | 88.59 Mn |
| Jun 30, 2022 | 98.43 Mn |
| Mar 31, 2022 | 231.21 Mn |
| Dec 31, 2021 | 9.68 Mn |
| Sep 30, 2021 | 116.25 Mn |